Retatrutide

Retatrutide
Clinical data
Other namesLY-3437943
Identifiers
IUPAC name
  • L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha -aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-Lleucyl-L-alpha -aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-Lphenylalanyl-L-isoleucyl-L-alpha -glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha -glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
UNII
ChEMBL
Chemical and physical data
FormulaC223H343F3N46O70
Molar mass4845.444 g·mol−1

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.[1] It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.[2][3][4] The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3.[5]

References

  1. ↑ Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept". Cell Metabolism. 34 (9): 1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340. S2CID 251675508.
  2. ↑ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight" (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
  3. ↑ Constantino, Annika Kim (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC. Retrieved 3 July 2023.
  4. ↑ Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (June 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine. 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID 37366315. S2CID 259260926. Free access subject to registration.
  5. ↑ "Compound Report Card". www.ebi.ac.uk. n.d.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.